抗體藥物複合體（ADC）市場規模、佔有率和成長分析：按產品、標靶、技術、應用和地區分類－2026-2033年產業預測

2024年全球抗體藥物複合體（ADC）市值為120.7億美元，預計將從2025年的131.3億美元成長到2033年的257.8億美元。預測期（2026-2033年）的複合年成長率預計為8.8%。

隨著全球癌症發病率上升和對創新藥物的需求不斷成長，抗體藥物複合體（ADC）的銷售額預計將顯著成長。此外，生物製藥研發投入的增加以及ADC開發技術的進步也推動了市場發展。加快核准流程以促進市場准入，預計也將對ADC的銷售產生正面影響。此外，個人化醫療的興起和廣泛應用也將支持市場擴張。然而，高昂的研發成本、與毒性相關的安全隱患以及來自生物相似藥的競爭等挑戰，對抗體藥物複合體領域的企業而言都是重要的阻礙因素，並可能阻礙市場的整體成長。

抗體藥物複合體(ADC) 市場按產品、標靶、應用、技術和地區進行細分。依產品分類，可分為 Cadsila、Enhertz、Adcetris、Padsev、Troderbi、Polibi 等公司。依應用分類，可分為血液腫瘤、乳癌、尿路上皮癌/膀胱癌和其他癌症。依標靶分類，可分為 HER2、CD22、CD30 等。依技術分類，可分為可裂解連接子、不可裂解連接子、無連接子、連接子技術類型、酬載技術等。依地區分類，可分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球抗體藥物複合體（ADC）市場促進因素

全球抗體藥物複合體(ADC) 市場正受到抗體工程、連接子化學和細胞毒性有效載荷領域重大創新的推動，這些創新正引領著新型高效抗體藥物複合體的開發。增強的偶聯技術實現了位點特異性藥物連接，從而提高了穩定性並降低了免疫抗原性。此外，各公司正在推動不可裂解連接子、雙藥 ADC 和雙特異性抗體的研究，以應對抗藥性問題。這些進展對於擴大治療範圍、擴大適應症和最大限度地減少副作用至關重要，最終將改變抗體藥物複合體療法的模式。

全球抗體藥物複合體（ADC）市場的限制因素

全球抗體藥物複合體（ADC）市場面臨許多可能阻礙其成長的重大挑戰。 ADC的生產製造需要複雜的設計、開發和生產流程，需要專門的設施進行抗體生成、細胞毒性藥物管理和偶聯操作。這種複雜性需要大量的資本投入，從而構成准入障礙。此外，嚴格的臨床前和臨床試驗階段對於確保安全性和有效性至關重要，導致研發成本高。這些因素綜合起來可能會限制抗體藥物複合體在市場上的滲透率和整體擴張。

全球抗體藥物複合體（ADC）市場趨勢

全球抗體藥物複合體(ADC) 市場正呈現出一個顯著的趨勢，即各公司正將其研發範圍擴展到癌症治療以外的領域。儘管傳統上 ADC 的研發重點是癌症治療，但人們對利用靶向特定免疫細胞的 ADC 來精準遞送免疫調節劑的興趣日益濃厚，尤其是在狼瘡和類風濕性關節炎等自體免疫疾病方面。此外，利用標靶病原體特異性標記物的 ADC 對抗細菌感染疾病的研究也不斷推進。 ADC 應用的多元化有望提升產生收入，並擴大這些創新生物製藥在多種疾病領域的治療效果。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

市場考察

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場吸引力指數
• PESTEL 分析
• 監理情勢

全球抗體藥物複合體（ADC）市場規模：按產品和複合年成長率分類（2026-2033 年）

• 門頭
• 恩哈特
• 阿德塞特里斯
• 帕德塞夫
• 特羅德爾比
• 波利維
• 其他

全球抗體藥物複合體（ADC）市場規模：以標靶和複合年成長率分類（2026-2033 年）

• HER2
• CD22
• CD30

全球抗體藥物複合體（ADC）市場規模：按應用和複合年成長率分類（2026-2033 年）

• 血癌
• 乳癌
• 尿路上皮癌
• 膀胱癌
• 其他癌症

全球抗體藥物複合體（ADC）市場規模：按技術和複合年成長率分類（2026-2033 年）

• 連接技術
  • 可切割連接器
  • 非切割連接子
  • 無連接器
• 有效載荷技術

全球抗體藥物複合體（ADC）市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要企業簡介

• Seagen, Inc.
• Takeda Pharmaceutical Company Ltd.
• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Gilead Sciences, Inc.
• Daiichi Sankyo Company Ltd.
• GlaxoSmithKline Plc
• Astellas Pharma, Inc.
• ADC Therapeutics SA
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Amgen Inc.
• Sanofi
• Incyte Corporation
• Janssen Pharmaceuticals（Johnson & Johnson）
• Servier Laboratories
• Regeneron Pharmaceuticals, Inc.
• Immunogen, Inc.

結論與建議

Global Antibody Drug Conjugates (ADC) Market size was valued at USD 12.07 Billion in 2024 and is poised to grow from USD 13.13 Billion in 2025 to USD 25.78 Billion by 2033, growing at a CAGR of 8.8% during the forecast period (2026-2033).

The increasing incidence of cancer globally, coupled with a growing demand for innovative pharmaceuticals, is anticipated to significantly boost the sales of antibody drug conjugates (ADCs). The market is further propelled by heightened investments in biopharmaceutical research and technological advancements in ADC development. Expedited approval processes designed to accelerate market entry are expected to positively impact ADC sales as well. Additionally, the rising trend towards personalized medicine and its wider adoption will support market expansion. However, challenges such as high development costs, safety concerns related to toxicity, and competition from biosimilars pose notable constraints for companies operating in the antibody drug conjugate sector, potentially hindering overall market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Drug Conjugates (ADC) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Drug Conjugates (ADC) Market Segments Analysis

The Antibody Drug Conjugates (ADC) Market is segmented based on the product, target, application, technology, and region. Based on the product, the Antibody Drug Conjugates (ADC) Market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others. Based on the application, the market is segmented into blood cancer,breast cancer, urothelial cancer & bladder cancer, and other cancer. Based on the target, the market is segmented into HER2, CD22, CD30, and others. On the basis of technology, the market is divided into cleavable linker, non-cleavable linker, linkerless, linker technology type, payload technology, and others. Based on Region it is categorized into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

Driver of the Global Antibody Drug Conjugates (ADC) Market

The Global Antibody Drug Conjugates (ADC) market is propelled by significant innovations in antibody engineering, linker chemistry, and cytotoxic payloads, which have resulted in the development of new and effective antibody drug conjugates. Enhanced conjugation techniques facilitate site-specific drug attachment, leading to improvements in stability and a reduction in immunogenicity. In addition, companies are investigating non-cleavable linkers, dual-drug ADCs, and bispecific antibodies as strategies to combat resistance. These advancements are crucial in expanding therapeutic windows, widening treatment indications, and minimizing adverse effects, ultimately transforming the landscape of antibody drug conjugate therapies.

Restraints in the Global Antibody Drug Conjugates (ADC) Market

The Global Antibody Drug Conjugates (ADC) market faces several significant challenges that may hinder its growth. The production of ADCs necessitates complex design, development, and manufacturing processes, which require specialized facilities tailored for antibody generation, cytotoxic drug management, and conjugation procedures. This complexity results in substantial capital investments that can be a barrier to entry. Furthermore, the high costs associated with research and development due to rigorous preclinical and clinical testing phases are essential for ensuring safety and efficacy. These combined factors could limit the widespread adoption and overall expansion of antibody drug conjugates in the market.

Market Trends of the Global Antibody Drug Conjugates (ADC) Market

The Global Antibody Drug Conjugates (ADC) market is witnessing a notable trend as companies expand their research and development efforts beyond oncology applications. While traditionally focused on cancer treatments, there is a growing interest in leveraging ADCs for various indications, particularly autoimmune disorders such as lupus and rheumatoid arthritis, by targeting specific immune cells for precise delivery of immunomodulatory agents. Furthermore, research is being directed towards combating bacterial infections through the targeting of pathogen-specific markers. This diversification of ADC applications is poised to enhance revenue generation and broaden the therapeutic impact of these innovative biopharmaceuticals across multiple disease areas.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Antibody Drug Conjugates (ADC) Market Size by Product & CAGR (2026-2033)

• Market Overview
• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

Global Antibody Drug Conjugates (ADC) Market Size by Target & CAGR (2026-2033)

• Market Overview
• HER2
• CD22
• CD30

Global Antibody Drug Conjugates (ADC) Market Size by Application & CAGR (2026-2033)

• Market Overview
• Blood Cancer
• Breast Cancer
• Urothelial Cancer
• Bladder Cancer
• Other Cancer

Global Antibody Drug Conjugates (ADC) Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Linker Technology
  • Cleavable Linker
  • Non-Cleavable Linker
  • Linkerless
• Payload Technology

Global Antibody Drug Conjugates (ADC) Market Size & CAGR (2026-2033)

• North America (Product, Target, Application, Technology)
  • US
  • Canada
• Europe (Product, Target, Application, Technology)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Target, Application, Technology)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Target, Application, Technology)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Target, Application, Technology)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Seagen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADC Therapeutics SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (Johnson & Johnson)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Servier Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunogen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations